DUBLIN--(Business Wire)--The
"Epiomic
Epidemiology Series: Fabry Disease Forecast In 21 Major Markets
2018-2028" report has been added to
ResearchAndMarkets.com's
offering.
This report provides the current prevalent population for Fabry Disease
across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK,
Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China,
South Korea, India, Australia, Brazil, Mexico, Argentina) split by
gender and 5-year age cohort. Along with the current prevalence, the
report also contains a disease overview of the risk factors, disease
diagnosis and prognosis along with specific variations by geography and
ethnicity.
Providing a value-added level of insight from the analysis team, several
of the main symptoms and co-morbidities of Fabry disease have been
quantified and presented alongside the overall prevalence figures. These
sub-populations within the main disease are also included at a country
level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Fabry disease include:
-
Angiokeratoma
-
Cornea verticillata (corneal whorling)
-
Hearing loss
-
Tinnitus
-
Proteinuria
-
Cardiac hypertrophy & arrhythmias
-
Sweating dysfunction
Reasons to buy
-
Able to quantify patient populations in global Fabry disease market to
target the development of future products, pricing strategies and
launch plans.
-
Gain further insight into the prevalence of the subdivided types of
Fabry disease and identify patient segments with high potential.
-
Delivery of more accurate information for clinical trials in study
sizing and realistic patient recruitment for various countries.
-
Provide a level of understanding on the impact from specific co-morbid
conditions on Fabry disease prevalent population.
-
Identify sub-populations within Fabry disease which require treatment.
-
Gain an understanding of the specific markets that have the largest
number of Fabry disease patients.
Key Topics Covered:
-
Cause of the Disease
-
Risk Factors & Prevention
-
Diagnosis of the Disease
-
Variation by Geography/Ethnicity
-
Disease Prognosis & Clinical Course
-
Key Comorbid Conditions/Features Associated with the Disease
-
Methodology for Quantification of Patient Numbers
-
Top-Line Prevalence for Fabry Disease
-
Features of Fabry Disease Patients
-
Abbreviations Used in the Report
-
Online Epidemiology Databases
-
Online Pharmaceutical Pricing Database
For more information about this report visit https://www.researchandmarkets.com/research/6xg6r7/fabry_disease_in?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005621/en/
ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs
